Abstract
Background
Idiopathic intracranial hypertension (IIH) is a neurological condition marked by elevated intracranial pressure (ICP) with no evident secondary cause, primarily affecting obese females of childbearing age. While acetazolamide is the standard medical therapy, weight loss is also considered a first-line treatment. Recently, glucagon-like peptide 1 (GLP-1) agonists have garnered interest for IIH management due to their weight reduction and potential CSF production-decreasing effects. This study evaluates the effect of GLP-1 agonists on ocular parameters of IIH.
Methods
A retrospective cohort study was conducted using data from 79 IIH patients who met the modified Dandy criteria and were diagnosed between January 2016 and July 2023. All included patients received acetazolamide, while some received additional therapy with a GLP-1 agonist, either liraglutide or semaglutide. The acetazolamide monotherapy group was compared with the combined therapy group. Data on ocular parameters and BMI changes were collected from the Soroka Medical Center’s electronic medical records. Patients with incomplete electronic documentation or with any history of invasive interventions were excluded from the study.
Results
When comparing 68 patients on acetazolamide alone to 11 patients on combined therapy with acetazolamide and GLP-1 agonists, no significant differences were found in any of the parameters: papilledema grade, best corrected visual acuity (BCVA), visual field (VF) or OCT RNFL thickness improvements over a 12-month period. Seven of the 11 patients in the combined therapy group completed the full year of follow up data and were included in the secondary outcome analysis, which revealed a trend of BMI reduction and possible acetazolamide dose reduction following GLP-1 initiation.
Conclusion
This study suggests that GLP-1 agonists effectively reduce BMI, a major risk factor for IIH. Moreover, our analysis of seven patients from the combined therapy group suggests that GLP-1 agonists allow for a reduction in acetazolamide dosage in the treatment of IIH without changing the clinical outcome.
Subject terms: Drug therapy, Outcomes research, Neurological disorders, Optic nerve diseases, Obesity
Introduction
Idiopathic intracranial hypertension (IIH) is a neurological disorder characterized by increased intracranial pressure (ICP) without a primary pathology [1]. Diagnosis of IIH is done using the modified Dandy criteria [2].
IIH predominantly affects obese women of childbearing age and is frequently associated with a spectrum of ocular morbidities, ranging from mild visual disturbances to severe vision loss [3, 4]. Current disease management focuses on lowering the ICP. Treatment primarily begins with a recommendation for weight reduction, which in certain cases may be sufficient alone to treat IIH [5]. When there is a threat of vision loss or other significant symptoms, medical treatment of IIH is usually initiated. Acetazolamide is the most common first-line medical treatment, aimed at reducing cerebrospinal fluid (CSF) production [6]. Other medications for the treatment of IIH include topiramate and furosemide, however, these are utilized much less often and both carry significant side effects.
Recently, glucagon-like peptide-1 (GLP-1) agonists have garnered significant interest in the management of IIH, primarily due to their distinct ability to promote weight loss. GLP-1 is a gut neuropeptide secreted by the distal small intestine in response to a meal. GLP-1 agonists signal at the hypothalamus to delay gastric emptying and regulate satiety, thereby promoting weight loss in the context of obesity [7].
Moreover, GLP-1 receptors were found to be expressed in the choroid plexus, the brain predominant CSF-secreting structure. A recent preclinical study demonstrated that GLP-1 receptor agonism can reduce CSF secretion, subsequently lowering ICP [8]. This unique mechanism makes GLP-1 agonists particularly promising for IIH therapy, as they not only address obesity, a major risk factor for IIH, but also directly target one of the central pathological processes of the condition [9]. To our knowledge, no study to date has investigated the effect of GLP-1 agonists on the visual parameters of IIH patients.
Our aim in this retrospective study is to evaluate the effect of GLP-1 agonists on ocular parameters in patients IIH.
Methods
The design of this study was a retrospective cohort study investigating the association between GLP-1 agonist use and ocular manifestations in IIH patients. Data was collected manually from electronic medical records of patients treated between January 2016 and July 2023 at Soroka University Medical Centre; a hospital located in the Southern region of Israel providing tertiary care to a population of close to 1 million people. All study procedures were conducted in accordance with the principles outlined in the Declaration of Helsinki and ethical approval was obtained from the Institutional Review Board (IRB) of Soroka University Medical Centre (approval number SOR-0350-16).
Patients included in the study were diagnosed with IIH using the modified Dandy criteria, consisting of: (1) signs and symptoms of increased intracranial hypertension, (2) normal neurological exam (except 6th nerve palsy and papilledema) including mental status examination, (3) no evidence of hydrocephalus, mass, structural, or vascular lesion on neuroimaging, (4) increased lumbar puncture opening pressure ( > 25 cm H2O), (5) Normal cerebral spinal fluid (CSF) contents, and (6) no other cause of increased ICP identified [2].
Patients with incomplete medical and ophthalmic documentation were excluded, as were patients with fulminant IIH or severe papilledema with visual compromise. Patients with prior invasive intervention (such as a placement of a venous stent, ventriculoperitoneal shunt placement, or optic nerve sheath fenestration) were also excluded. Age, sex, and past medical history such as diabetes or hypertension were not considered as inclusion or exclusion criteria. 79 patients were included in the study.
The patients were divided into two groups: the acetazolamide group, who received daily acetazolamide treatment only, and the GLP-1 group, who received daily acetazolamide and combined this therapy with either liraglutide (Saxenda) or semaglutide (Ozempic). No other brands of GLP-1 agonists or dual GLP-1/GIP agonists were used. The initiation date of the patient’s prescription for GLP-1 medications by their primary care physicians was documented, including whether Saxenda or Ozempic was given, along with the dosages prescribed. Additionally, the starting date and dose of Uramox (acetazolamide) usage was tracked for all study patients, as well as any changes in dosage, and the patient’s BMI from the beginning of the treatment through 12 months of follow-up was recorded. Lumbar puncture opening pressures were taken only at the initial work-up visit for most of these patients, so repeat pressure measurements throughout treatment were not available for analysis.
Primary outcomes
We analysed four ocular parameters: degree of papilledema using the Frisén scale from 0 (normal) to 5 (severe papilledema), best-corrected visual acuity (BCVA) expressed as logMAR, visual field (VF) evaluations with SITA Fast 30-2 algorithm, and retinal nerve fibre layer (RNFL) thickness via OCT. Comparison between the groups was done at baseline (start of treatment with GLP-1 or acetazolamide) and at 3, 6, and 12 months post-treatment initiation. All measurements were performed by hospital-based neuro-ophthalmologists and ophthalmic technicians.
Secondary outcomes
In the secondary outcomes analysis, our study aimed to investigate the potential impact of GLP-1 agonist therapy on the dosage of acetazolamide within the treatment protocol. Additionally, we evaluated changes in BMI within the two treatment groups.
Statistical analysis
Descriptive statistics were presented by two main study groups, patients receiving acetazolamide alone and patients receiving both acetazolamide and a GLP-1 agonist. Primary outcomes were presented graphically over time using scatter plots. All quantitative variables were presented using mean ± standard deviation (SD), median and range. Categorical variables were presented with counts and percentages out of available cases. The threshold for statistical significance was set at a p value < 0.05.
Univariable analysis was performed using Wilcoxon rank sum test for continuous non-normal variables and Chi square or Fisher’s exact test for categorical variables. To compare quantitative variables across time points and between groups, a random intercept logistic regression was used. No imputation of missing data was conducted.
To examine the ocular manifestations before and after GLP-1 agonist treatment onset, the mean value of the four ocular parameters per eye, before and after the onset of treatment with GLP-1, was calculated and presented graphically using scatter plots. In the GLP-1 agonist group, BMI and acetazolamide dosage were examined for potential association and presented on scatter plots over time, per patient.
To examine the relationship between taking a GLP-1 agonist and ocular manifestations over time, while accounting for repeated measurements within patients, a generalized estimating equation (GEE) model was used with a Poisson distribution applied to the study outcomes and an autoregressive correlation structure.
As a part of a sensitivity analysis, the main comparisons in the study were repeated for the study groups matched by nearest age and BMI. Statistical analysis was conducted using R v.4.3.1.
Results
The study included 79 patients diagnosed with IIH according to our eligible criteria. The acetazolamide group included 68 patients with an average age of 23 ± 10 years, the GLP-1 agonist group included 11 patients with an average age of 30 ± 14 (p = 0.13). Both groups had a similar gender distribution with 82% female in each group (p > 0.9). Due to the small number of male patients in our cohort, we could not perform a separate analysis of sex differences in outcomes. There was a significant difference in the baseline BMI between the two groups, with the acetazolamide group having a mean BMI of 32 ± 8 compared to 38 ± 8 in the GLP-1 agonist group (p = 0.032). This difference in BMI remained significant throughout follow up, as post-treatment mean BMI in the acetazolamide group was 31 ± 8, while the post-treatment GLP-1 agonist group had a mean BMI of 37 ± 7 (p = 0.017). Lumbar puncture opening pressure measurement averages from the initial work-up visit were similar between the two groups (Table 1).
Table 1.
Demographics and pre-/post-treatment BMIs of study participants by group.
| Characteristic | Acetazolamide, N = 681 | GLP-1 Agonist, N = 11a | p valueb |
|---|---|---|---|
| Age (years) |
23 ± 10 22 5, 48 |
30 ± 14 27 15, 64 |
0.13 |
| Gender - female | 56 (82%) | 9 (82%) | >0.9 |
| BMI (pre-treatment) |
32 ± 8 31 14, 57 |
38 ± 8 36 31, 58 |
0.032 |
| BMI (post-treatment) |
31 ± 8 30 13, 61 |
37 ± 7 36 28, 54 |
0.017 |
| Initial lumber puncture opening pressure (mmHg) |
347 ± 108c 320 90, 550 |
335 ± 83 310 260, 550 |
0.6 |
aMean ± SD
Median
Range, n (%).
bWilcoxon rank sum test; Fisher’s exact test
cFive patients were missing lumbar puncture opening pressure data from their electronic medical records, N = 63.
All 79 patients were treated with oral acetazolamide (PO) at daily doses ranging from 500 mg to 1000 mg, and 11 of these patients were additionally treated with GLP-1 agonists—either liraglutide (Saxenda) or semaglutide (Ozempic). Liraglutide was administered as a subcutaneous injection once weekly at a dose of 0.6 mg, while semaglutide was administered as a subcutaneous injection once weekly at a dose of 0.25 mg. The dosage of acetazolamide was determined according to the neuro-ophthalmologist’s recommendations, whereas the dosage of GLP-1 agonists was decided by the family doctor. Table 1 compares the characteristics of participants treated with acetazolamide only and acetazolamide alongside GLP-1 agonists.
Primary outcomes
The comparative analysis of BCVA scores between the two groups demonstrated a significant improvement in the GLP-1 agonist group at the 6-month mark (0.18 ± 0.17 vs 0.08 ± 0.15, p = 0.031, Table 2) compared to the acetazolamide group, with no significant differences noted at baseline, 3 months, or 12 months. No significant differences in papilledema scores, VF scores or RNFL thickness on OCT were observed between the two groups throughout the follow-up time points (Table 2). No statistically significant difference between lumbar puncture opening pressure and visual outcomes was found.
Table 2.
Comparison of visual outcomes in acetazolamide and GLP-1 agonist treatment groups at different follow-up time points.
| Outcome | Time Point | Acetazolamide, N = 22a | GLP-1 Agonist, N = 22a | p valueb |
|---|---|---|---|---|
| Papilledema (Frisén Scale) | baseline |
1.55 ± 1.30 1.50 0.00, 4.00 |
1.27 ± 1.45 1.00 0.00, 4.00 |
0.081 |
| 3 months |
1.20 ± 1.01 1.00 0.00, 3.00 |
0.89 ± 1.32 0.00 0.00, 4.00 |
0.8 | |
| 6 months |
0.50 ± 0.52 0.50 0.00, 1.00 |
0.33 ± 0.49 0.00 0.00, 1.00 |
0.8 | |
| 12 months |
0.14 ± 0.36 0.00 0.00, 1.00 |
0.50 ± 0.71 0.00 0.00, 2.00 |
0.083 | |
| Visual Field | baseline |
–1.9 ± 2.0 –1.6 –5.1, 0.8 |
–3.7 ± 3.6 –2.0 –10.7, 0.7 |
0.8 |
| 3 months |
–0.93 ± 1.39 –1.31 –2.35, 1.54 |
–3.04 ± 3.61 –1.49 –10.69, 0.38 |
0.8 | |
| 6 months |
–1.3 ± 1.6 –0.9 –4.4, 0.1 |
–5.0 ± 4.2 –3.7 –12.6, –0.6 |
0.7 | |
| 12 months |
–0.40 ± 0.77 –0.36 –1.67, 0.62 |
–1.69 ± 3.10 –0.51 –10.03, 0.27 |
0.8 | |
| Best Corrected Visual Acuity (logMAR) | baseline |
0.10 ± 0.10 0.06 0.00, 0.20 |
0.13 ± 0.38 0.00 0.00, 1.80 |
0.8 |
| 3 months |
0.07 ± 0.10 0.00 0.00, 0.30 |
0.11 ± 0.12 0.05 0.00, 0.30 |
>0.9 | |
| 6 months |
0.08 ± 0.15 0.00 0.00, 0.47 |
0.18 ± 0.17 0.20 0.00, 0.60 |
0.031 | |
| 12 months |
0.02 ± 0.06 0.00 0.00, 0.20 |
0.06 ± 0.08 0.00 0.00, 0.20 |
0.7 | |
| Optical Coherence Tomography Retinal Nerve Fibre Layer | baseline |
161 ± 91 128 87, 346 |
103 ± 20 99 76, 147 |
0.13 |
| 3 months |
124 ± 47 107 85, 265 |
97 ± 18 103 58, 126 |
0.2 | |
| 6 months |
100 ± 11 97 86, 128 |
95 ± 22 100 57, 123 |
0.9 | |
| 12 months |
99 ± 11 96 86, 124 |
95 ± 28 101 54, 142 |
>0.9 |
aMean ± SD
Median
Range
brandom intercept logistic regression.
Secondary outcomes
Only seven of the original 11 combination therapy group patients had complete data for the full one-year follow-up period before and after initiation of treatment, and thus only these seven patients were included in the secondary outcome analysis. In Fig. 1, each graph represents the data for an individual patient. Among the seven patients analysed, two experienced a reduction in BMI, four maintained a relatively stable BMI with minor fluctuations, and one patient showed an increase in BMI following the onset of GLP-1 agonist treatment. Most notably, five of the patients demonstrated a reduction in the dose of acetazolamide.
Fig. 1. Acetazolamide dose and BMI in individual patients before and after GLP-1 agonist initiation.
Panels A–G represent individual patients. Solid black lines indicate acetazolamide dose (left Y-axis), and dashed blue lines indicate BMI (right Y-axis). The vertical dashed line marks GLP-1 agonist initiation.
Discussion
In this study, we aimed to evaluate the impact of adding GLP-1 agonists in the treatment of IIH by measuring four ocular parameters. Although the analysis revealed statistically significant differences at the 6-month mark for BCVA improvement in the GLP-1 agonist group, there was no continued statistically significant improvement at 12 months and thus no significant differences following treatment completion between the two groups in these parameters.
However, there were significant differences in the baseline characteristics of the two groups. The GLP-1 agonist group began with a higher mean BMI, which is often associated with a more complicated disease course [10]. In this case, it is noteworthy that the GLP-1 agonist group had no worse visual outcomes compared to the acetazolamide monotherapy group across all primary outcome measures despite the increased risk due to their higher baseline BMI.
In our secondary outcomes analysis, we aimed to investigate the potential impact of GLP-1 agonist therapy on the dosage of acetazolamide and evaluate changes in BMI during GLP-1 administration. As expected, we observed a decrease in the BMI of patients following the initiation of GLP-1 agonists. More significantly, we noted a reduction in the dosage of acetazolamide, which was temporally correlated with the introduction of GLP-1 agonist therapy. This reduction in acetazolamide dosage is particularly important given that acetazolamide is associated with a variety of side effects, including cognition and memory impairment, that can negatively impact patient adherence to treatment [11, 12]. Therefore, the inclusion of GLP-1 agonists may not only aid in management of IIH by promoting weight loss but also allows for a decrease in acetazolamide dosage, potentially improving patient compliance and overall treatment outcomes [6, 13].
Acetazolamide was the only drug investigated in combination with GLP-1 agonists for IIH treatment as virtually all new IIH cases in our medical centre are given acetazolamide as first-line medical therapy. Additionally, measuring the ICP by lumbar puncture is an invasive procedure that is not warranted in most cases following the diagnosis of IIH. While our study did not include follow up ICP measurements, the reduction in the Frisen grade and RNFL thickness may serve as surrogate markers for the reduction of ICP.
Very few other studies have investigated GLP-1 agonist effects on ocular parameters in IIH, with one recent article similarly finding that while ocular manifestations were not changed significantly during a 6-month follow-up period, adding GLP-1 agonists did allow for lower dosages of acetazolamide and promoted weight loss with no reported significant adverse events [14]. While not addressed by this study, future research may investigate whether GLP-1 agonists can serve as a standalone treatment for IIH.
This study had several limitations to consider, including a small sample size and a relatively short follow-up period, both potentially influencing the study’s ability to derive substantial statistical findings. It is possible that longer follow-up or a larger sample size could reveal more definitive trends. Although trained neuro-ophthalmologists conducted the evaluations using the Frisén scale as a standardized tool, this may have introduced some inter-observer variability in grading. The retrospective nature of the study may have also introduced biases affecting the reliability of the results, though hopefully mitigated by the use of matched controls. While the information regarding the changes in ganglion cell layer thickness might have added some perspective regarding the effects of longstanding papilledema in both groups, we did not have a compete record of this data for many of the patients and it was omitted.
A key limitation of this study was that ICP was not measured repeatedly following the diagnosis for many of our patients, and therefore we were unable to directly assess the relationship between ICP changes and visual outcomes. Future studies with repeat ICP measurements throughout patient follow-up may be able to ascertain whether reduction of acetazolamide dose or improvement in visual outcomes can be attributed to the changing ICP. Additionally, we don’t have information on how the titration of GLP-1 dosages over time may have affected visual outcomes, or on patients who discontinued GLP-1 treatment after our follow-up ended, whether their weight loss was sustained, and their risk for disease relapse. Lifestyle habits or inter follow-up events were not considered, which may have confounded the results. Due to the retrospective nature of this study, we could not determine whether the reduction in BMI seen in the GLP-1 group was the primary driver contributing to visual improvement, and future studies may want to further explore this relationship. Additionally, future research with larger cohorts, longer follow-up periods, and prospective study designs is essential to confirm these findings and fully understand the long-term benefits and potential of GLP-1 agonists in the treatment of IIH.
Conclusion
While GLP-1 agonists are increasingly used for the treatment of obesity, they may have a similarly increasingly important role in the treatment of IIH as well. In this small-scale study we showed similar results in visual outcomes over 12 months of follow-up, despite the fact that a high percentage of patients in the GLP-1 group were able to lower their acetazolamide dosage during treatment. Although further studies with larger populations and longer follow-up is needed, GLP-1 agonists may help patients achieve the same clinical outcomes using lower doses of ICP-lowering medication in the treatment of IIH.
Summary
What was known before
- Glucagon-like peptide-1 (GLP-1) agonists have garnered significant interest in the management of IIH, primarily due to their ability to promote weight loss.
- Moreover, GLP-1 receptors were found to be expressed in the choroid plexus, the brain predominant CSF-secreting structure. Recent preclinical work has demonstrated that GLP-1 receptor agonism can reduce CSF secretion, subsequently lowering ICP.
What this study adds
Very little previous research has been done to evaluate the effect of GLP-1 agonists on ocular parameters in patients IIH.
Supplementary information
Author contributions
Study Conceptualization and Methodology Design: LK, AH, ET. Data Curation: LK, SL, TR, MW, KB, WH, YE. Formal Statistical Analysis: MO, TK. Table and Figure Creation: SL, MO, TK. Writing—Original Draft, Review and Editing: LK, SL, EW. Oversight: ET.
Data availability
The datasets generated during and/or analysed during the current study are not publicly available due to the privacy of patient information, but can be requested from the corresponding author upon reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
The online version contains supplementary material available at 10.1038/s41433-025-03807-0.
References
- 1.Kalyvas A, Neromyliotis E, Koutsarnakis C, Komaitis S, Drosos E, Skandalakis G et al. A systematic review of surgical treatments of idiopathic intracranial hypertension (IIH), Apr. 01, 2021, Springer Science and Business Media Deutschland GmbH. 10.1007/s10143-020-01288-1. [DOI] [PubMed]
- 2.Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension, 2002. 10.1212/01.WNL.0000029570.69134.1B. [DOI] [PubMed]
- 3.Wall M, Kupersmith M, Kieburtz K, Corbett J, Feldon S, Friedman D et al. The idiopathic intracranial hypertension treatment trial clinical profile at baseline. JAMA Neurol. 71, 2014, 10.1001/jamaneurol.2014.133. [DOI] [PMC free article] [PubMed]
- 4.Raoof N, Hoffmann J. Diagnosis and treatment of idiopathic intracranial hypertension. Cephalagia. 2021. 10.1177/0333102421997093. [DOI] [PMC free article] [PubMed]
- 5.Subramaniam S, Fletcher WA. Obesity and weight loss in idiopathic intracranial hypertension: a narrative review, 2017. 10.1097/WNO.0000000000000448. [DOI] [PubMed]
- 6.Souza MNP, Costa BdeAL, Santos FRDR, Fortini I. Update on idiopathic intracranial hypertension management, Arq Neuropsiquiatr. 80, 2022, 10.1590/0004-282X-ANP-2022-S110. [DOI] [PMC free article] [PubMed]
- 7.Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–56. 10.1016/j.cmet.2018.03.001. [DOI] [PubMed] [Google Scholar]
- 8.Botfield H, Uldall M, Westgate C, Mitchell J, Hagen S, Gonzalez A, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9:eaan0972. 10.1126/scitranslmed.aan0972. [DOI] [PubMed] [Google Scholar]
- 9.Mitchell J, Lyons H, Walker J, Yiangou A, Grech O, Alimajstorovic Z et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023, 10.1093/brain/awad003. [DOI] [PMC free article] [PubMed]
- 10.Thaller M, Homer V, Hyder Y, Yiangou A, Liczkowski A, Fong A et al. The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes. J Neurol. 270, 2023, 10.1007/s00415-022-11402-6. [DOI] [PMC free article] [PubMed]
- 11.Vahedi K, Taupin P, Djomby R, El-Amrani M, Lutz G, Filipetti V, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol. 2002;249:206–11. 10.1007/pl00007866. [DOI] [PubMed] [Google Scholar]
- 12.Grech O, Mitchell J, Lyons H, Yiangou A, Thaller M, Tsermoulas G, et al. Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension. Eye. 2024;38:1374–9. 10.1038/s41433-023-02908-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: The idiopathic intracranial hypertension treatment trial. JAMA. 2014;311:16 10.1001/jama.2014.3312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M et al. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 24, 2023, 10.1186/s10194-023-01631-z. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets generated during and/or analysed during the current study are not publicly available due to the privacy of patient information, but can be requested from the corresponding author upon reasonable request.

